gist at the Harvard School of Public Health, sees several fundamental errors in the way many researchers tackle microarray gene-expression studies. "People tend to go out blindly and do experiments, then go back and try to analyse them and figure out what the question is afterwards. I think that's the first thing you have to avoid, " he says. "It's also important to make sure you remove confounding factors from the experiment wherever possible. "
Systematically sorting out sources of error can be a daunting process, but a recent series of investigations by people such as Quackenbush into cross-experimental, cross-platform and cross-laboratory variability between array experiments has helped clarify some issues that were preventing comparisons being made between experiments. Several multi-institutional projects are now under way to develop more reliable experimental protocols and controls (see 'Standards and practices'). Meanwhile, many scientists, manufacturers and programmers are working to develop practical tools that could help eliminate unwanted variability from experiments and analyses.
The biggest problems often occur early on. Existing kits for RNA preparation are effective, but many are designed for a 'best-case sce- a vast reference data set," says Shi. "We have conducted more than 1,000 array hybridizations with these reference samples, plus we're using three alternative technologies and we requested that each system be evaluated at three testing sites." The MAQC recently completed a review of its final data, and will present its findings in a series of articles to be published in Nature Biotechnology next month.
In the meantime, many in the field are awaiting the outcome of a complementary initative: the External RNA Controls Consortium (ERCC). This evolved from a 2003 meeting headed by the US National Institute of Standards and Technology in Gaithersburg, Maryland. It aims to identify and help make commercially available a collection of reliable RNA 'spike-in' controls, which can be included in any microarray experiment to assess variables such as labelling and hybridization efficiency. Participation has grown rapidly, and ERCC leader Janet Warrington, who is a vice-president at Affymetrix in Santa Clara, California, finds the early progress promising. "A number of organizations that were already using their own controls have donated these -no strings attached -for testing," she says. "So we have a collection of 100 to 150 controls that will be tested across platforms and we have eight sites that have volunteered to carry out the testing."
Both projects have benefited from collaborative environments that have allowed even direct competitors to work together towards a shared goal. "We all share the belief that if we're successful, we'll expand the marketplace for everyone," says Warrington.
M.E.
STANDARDS AND PRACTICES
Affymetrix's tiling and exon arrays: two alternatives for in-depth screening of the human genome.
Leming Shi hopes to improve the reproducibility and comparability of microarray work.
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